Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide(As2O3)in the treatment of acute promyelocytic leukemia(APL):Ⅱ. Clinical efficacy and pharmacokinetics in relapsed patients[J]. Blood, 1997, 89(9): 3354-3360.
[5]
Han B, Zhou G, Zhang Q, et al. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp[J]. J Exp Ther Oncol, 2004, 4(4): 335-342.
[6]
Matsui W, Smith BD, Vala M, et al. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukemia[J]. Br J Haematol, 2005, 128(6): 853-862.
[7]
Karasulu HY, Karabulut B, Kantarci G, et al. Preparation of arsenic trioxide loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line[J]. Drug Deliv, 2004, 11(6): 345-350.
[8]
Kang SH, Song JH, Kang HK, et al. arsenic trioxide-induced apoptosis is in dependent of stress-responsive signaling pathway but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cell[J]. Exp Mol Med, 2003, 35(2): 83-90.
[9]
Li H, Zhu X, Zhang Y, et al. Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction[J]. J Exp Clin Cancer Res, 2009, 28: 110.
[ 4 ] Steger V, Mika U, Toomes H, et al. Who gain most A 10-year experience with 611 thoracoscopic talc pleurodeses[J]. J Ann Thorac Surg, 2007, 83(6): 1940-1945.
[13]
[ 5 ] Aelony Y. Dry talc pleurodesis via chest tube[J]. Chest, 2003, 123(1): 308.
[14]
[ 6 ] Neragi Miandoab S. Malignant pleural effusion current and evolving approaches for its diagnosis and management[J]. Lung Cancer, 2006, 54(1): 1-9.
[15]
[ 7 ] Cerimagic Z, Guska S, Pilav I, et al. The using doxycycline in procedure chemical pleurodesis of malignancy pleural effusion[J]. Med Arh, 2006, 60(6): 360-363.
